(Reuters) -AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously... Read more
Usnews - Nov 21
The qualitative latest Research report (2025-2032) on the Nut Midline Carcinoma Treatment Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using Read more
Openpr.com - Nov 12
AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about which drug may be better. Read more
Stat - Oct 19
Pharmaceutical giant AstraZeneca will offer U.S. patients discounted prices for some drugs, President Trump announced Friday, the second major drug company to strike a deal with the administration. Read more
Cbs News - Oct 11
Company to sell some medicines at a discount to US’s Medicaid health plan in exchange for tariff reliefDonald Trump announced a deal with the British-based drugmaker AstraZeneca for a “most-favored-nation” drug-pricing model aimed at making prescription medicines more affordable and avoiding the ... Read more
The Guardian - Oct 10
The US president told reporters he didn't think the deal would have been possible without his 100-percent tariff threat. Read more
Al Jazeera - Oct 10
TrumpRx.gov, a website where Americans can buy pharmaceutical drugs under President Donald Trump’s new drug pricing plan, is set to begin operation in 2026 Read more
The Independent - Oct 10
Construction is underway on pharmaceutical giant AstraZeneca's $4.5 billion plant in Albemarle County, which promises to employ 600 people producing weight-loss drugs. Read more
The Daily Progress - Oct 09
AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo on Monday released high-level results from the TROPION-Breast02 Phase 3 trial.The trial is evaluating Datroway (datopotamab deruxtecan) versus the investigator’s choice of chemotherapy (paclitaxel, nab-paclitaxel, capecitabine, carboplatin, or eribu... Read more
Benzinga - Oct 06
On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AstraZeneca PLC (NASDAQ:AZN) as his final trade.On Aug. 20, AstraZeneca released complete results from the BaxHTN Phase 3 trial evaluating baxdrostat. The Cambridge, U.K.-based company released the toplin... Read more
Benzinga - Sep 04
